URGN Q3 2019 Earnings — UroGen Pharma Ltd. Revenue & Financial Results | Market Cap Arena

URGNUroGen Pharma Ltd.

$918M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

-$23M

Operating Income

-$23M

Net Income

-$22M

EPS (Diluted)

$-1.06

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$227M

Total Liabilities

$16M

Stockholders' Equity

$211M

Cash & Equivalents

$66M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$283,000	-100.0%
Gross Profit	-$23M	-$772,000	-2938.0%
Operating Income	-$23M	-$21M	-11.2%
Net Income	-$22M	-$21M	-8.4%